New leukemia combo aims to stop treatment for years
NCT ID NCT06524375
Summary
This study is testing if adding a drug called venetoclax to a standard first-line treatment (a BTK inhibitor) can lead to a very deep and lasting remission in people with chronic lymphocytic leukemia (CLL). The goal is to get the cancer down to such low levels that patients might be able to safely stop all treatment for a period of time. It will involve about 118 participants who are already responding well to their current BTK inhibitor therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817-1915, United States
-
Asante Rogue Regional Medical Center
Medford, Oregon, 97504-8332, United States
-
Astera Cancer Care East Brunswick
East Brunswick, New Jersey, 08816-4096, United States
-
Cancer Specialists of North Florida
Jacksonville, Florida, 32256-6932, United States
-
Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center
Boston, Massachusetts, 02215-5418, United States
-
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana, 46804, United States
-
Highlands Oncology Group
Springdale, Arkansas, 72762, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Mission Blood and Cancer - MercyOne Cancer Center
Des Moines, Iowa, 50314-3030, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130-2042, United States
-
Nebraska Cancer Specialists St Francis - Grand Island
Grand Island, Nebraska, 68803, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Oncology Hematology Care Inc - Cincinnati - USOR
Cincinnati, Ohio, 45236-2725, United States
-
Rocky Mountain Cancer Centers (Aurora) - USOR
Aurora, Colorado, 80012-5405, United States
-
San Juan Oncology Associates, PC
Farmington, New Mexico, 87401, United States
-
Tennessee Oncology - Midtown
Nashville, Tennessee, 37203, United States
-
Tennessee Oncology, PLLC - Chattanooga
Chattanooga, Tennessee, 37404, United States
-
Texas Oncology- Northeast Texas
Tyler, Texas, 75702, United States
-
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, 97401-6043, United States
Conditions
Explore the condition pages connected to this study.